UA27728C2 - Похідні піразолу, що мають спорідненість до рецепторів канабіноїдів, спосіб їх одержання, фармацевтична композиція та проміжна сполука - Google Patents

Похідні піразолу, що мають спорідненість до рецепторів канабіноїдів, спосіб їх одержання, фармацевтична композиція та проміжна сполука

Info

Publication number
UA27728C2
UA27728C2 UA93002472A UA93002472A UA27728C2 UA 27728 C2 UA27728 C2 UA 27728C2 UA 93002472 A UA93002472 A UA 93002472A UA 93002472 A UA93002472 A UA 93002472A UA 27728 C2 UA27728 C2 UA 27728C2
Authority
UA
Ukraine
Prior art keywords
affinity
preparation
pharmaceutical composition
pyrazole derivatives
intermediate compound
Prior art date
Application number
UA93002472A
Other languages
English (en)
Russian (ru)
Inventor
Франсі Барт
Франси Барт
П'єр Казелла
Пьер Казелла
Крістіан Конжі
Кристиан Конжи
Серж Мартінез
Серж Мартинез
Мюрьєль Рінальді
Мюрьель Ринальди
Original Assignee
Санофі
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9431062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA27728(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофі filed Critical Санофі
Publication of UA27728C2 publication Critical patent/UA27728C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Даний винахід належить до нових похідних піразолу. Він стосується також способу їх одержання, фармацевтичних композицій на їх основі та проміжних сполук для їх синтезу.
UA93002472A 1992-06-23 1993-06-18 Похідні піразолу, що мають спорідненість до рецепторів канабіноїдів, спосіб їх одержання, фармацевтична композиція та проміжна сполука UA27728C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9207645A FR2692575B1 (fr) 1992-06-23 1992-06-23 Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
UA27728C2 true UA27728C2 (uk) 2000-10-16

Family

ID=9431062

Family Applications (1)

Application Number Title Priority Date Filing Date
UA93002472A UA27728C2 (uk) 1992-06-23 1993-06-18 Похідні піразолу, що мають спорідненість до рецепторів канабіноїдів, спосіб їх одержання, фармацевтична композиція та проміжна сполука

Country Status (26)

Country Link
US (1) US5624941A (uk)
EP (1) EP0576357B1 (uk)
JP (1) JP3238801B2 (uk)
KR (1) KR100307050B1 (uk)
AT (1) ATE149489T1 (uk)
AU (1) AU664281B2 (uk)
BR (2) BR9302435A (uk)
CA (1) CA2098944C (uk)
CZ (1) CZ289487B6 (uk)
DE (1) DE69308395T2 (uk)
DK (1) DK0576357T3 (uk)
ES (1) ES2101258T3 (uk)
FI (1) FI113169B (uk)
FR (1) FR2692575B1 (uk)
GR (1) GR3023535T3 (uk)
HU (2) HU218797B (uk)
IL (2) IL106099A (uk)
MX (1) MX9303664A (uk)
MY (1) MY113022A (uk)
NO (1) NO302819B1 (uk)
NZ (1) NZ247961A (uk)
RU (1) RU2119917C1 (uk)
SK (1) SK283399B6 (uk)
TW (1) TW494096B (uk)
UA (1) UA27728C2 (uk)
ZA (1) ZA934511B (uk)

Families Citing this family (364)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2713224B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
AU3577995A (en) * 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
FR2732967B1 (fr) * 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
DE19706903A1 (de) 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
WO1998041519A1 (en) * 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
JP2002512188A (ja) 1998-04-21 2002-04-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗酸化剤及び神経保護剤としてのカンナビノイド類
DE69910373T2 (de) * 1998-05-04 2004-04-01 The University Of Connecticut, Farmington Analgetische und immunomodulierende cannabinoiden
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US6274635B1 (en) 1999-03-22 2001-08-14 Immugen Pharmaceuticals Inc. Alkylated resorcinol derivatives for the treatment of immune diseases
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CO5370679A1 (es) 1999-06-01 2004-02-27 Smithkline Beecham Corp Inhibidores fab 1
PT1144382E (pt) 1999-08-03 2005-02-28 Ortho Mcneil Pharm Inc Processo para a preparacao de 1,5-diaril-3-(substituido)pirazoles
FR2799124B1 (fr) * 1999-10-01 2004-08-13 Sanofi Synthelabo Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
AU7866300A (en) * 1999-10-08 2001-04-23 Smithkline Beecham Corporation Fab i inhibitors
JP4803935B2 (ja) * 1999-10-08 2011-10-26 アフィニアム・ファーマシューティカルズ・インコーポレイテッド Ｆａｂｉ阻害剤
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
CA2286442A1 (en) * 1999-10-15 2001-04-15 Universite De Montreal Compositions for increasing the concentration of cannabinoids as vasodilators and cardioprotectors againts ischaemia
US8084467B2 (en) 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
DE60033834T2 (de) 1999-10-18 2007-11-15 The University Of Connecticut, Farmington Für periphäre cannabinoid-rezeptoren selektive liganden
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
CA2387892A1 (en) * 1999-10-18 2001-04-26 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7741365B2 (en) 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
FR2800372B1 (fr) 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
ATE346047T1 (de) 2000-03-23 2006-12-15 Solvay Pharm Bv 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer aktivität
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US20020091114A1 (en) * 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
JP2004532185A (ja) 2001-01-26 2004-10-21 ユニバーシティ オブ コネチカット 新規なカンナビミメティックリガンド
DE60237431D1 (de) 2001-01-29 2010-10-07 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
AR033046A1 (es) * 2001-03-22 2003-12-03 Solvay Pharm Bv Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1, composicion farmaceutica y metodos de preparacion
EP1560584B1 (en) * 2001-04-06 2009-01-14 Affinium Pharmaceuticals, Inc. Fab i inhibitors
JP4312594B2 (ja) * 2001-07-13 2009-08-12 ユニバーシティ オブ コネチカット 新規な二環式及び三環式カンナビノイド
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
MXPA04001071A (es) * 2001-08-06 2004-05-20 Astrazeneca Ab Dispersion acuosa que comprende nanoparticulas estables de un activo insoluble en agua y un excipiente como trigliceridos de cadena media (mct).
EP1419161A1 (en) 2001-08-24 2004-05-19 PHARMACIA & UPJOHN COMPANY Substituted-heteroaryl-7-aza 2.2.1]bicycloheptanes for the treatment of disease
JP2005507875A (ja) * 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
PL368441A1 (en) * 2001-09-21 2005-03-21 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
EP1429762A1 (en) * 2001-09-21 2004-06-23 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
AR036608A1 (es) * 2001-09-24 2004-09-22 Bayer Corp Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad
WO2003035005A2 (en) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
JP2005511613A (ja) * 2001-11-08 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患治療用アザビシクロ置換ヘテロアリール化合物
US20040171613A1 (en) * 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7351729B2 (en) * 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
CA2478183C (en) * 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
AU2003214226A1 (en) * 2002-03-18 2003-10-08 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
JP2005528366A (ja) * 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
CA2479744A1 (en) * 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
AU2003223510B2 (en) * 2002-04-12 2008-05-08 Merck Sharp & Dohme Corp. Bicyclic amides
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
KR101228376B1 (ko) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
WO2004013137A1 (en) 2002-08-01 2004-02-12 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
CN1678303A (zh) 2002-08-23 2005-10-05 康涅狄格大学 具有治疗作用的酮类大麻类
US7319110B2 (en) * 2002-09-19 2008-01-15 Solvay Pharmaceuticals B.V. 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
CA2502511A1 (en) * 2002-10-18 2004-05-29 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
DK1575951T3 (da) * 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
EP1583742B1 (en) 2003-01-02 2009-12-02 F. Hoffmann-La Roche Ag Cb 1 receptour inverse agonists
DE60322114D1 (de) 2003-01-02 2008-08-21 Hoffmann La Roche Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
PL377848A1 (pl) * 2003-02-07 2006-02-20 Daiichi Pharmaceutical Co., Ltd. Pochodne pirazoli
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
JP4880448B2 (ja) 2003-03-17 2012-02-22 アフィナム ファーマシューティカルズ，インコーポレーテッド 複数の抗生物質を含む組成物、及びそれを用いる方法
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
EP1622876A1 (en) * 2003-05-07 2006-02-08 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
KR20110117731A (ko) * 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2004247615B2 (en) * 2003-06-18 2008-02-21 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as CB1 modulators
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
RU2344132C2 (ru) 2003-06-20 2009-01-20 Ф.Хоффманн-Ля Рош Аг 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN1902177A (zh) 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
BRPI0417376A (pt) 2003-12-08 2007-04-10 Hoffmann La Roche compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
JP2007084437A (ja) * 2003-12-26 2007-04-05 Dai Ichi Seiyaku Co Ltd アミノアルキルピラゾール誘導体
FR2864958B1 (fr) * 2004-01-12 2006-02-24 Sanofi Synthelabo Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
KR100843023B1 (ko) 2004-01-28 2008-07-01 에프. 호프만-라 로슈 아게 스피로-5환 화합물
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
ES2329915T3 (es) * 2004-02-20 2009-12-02 Astrazeneca Ab Derivados de 1,5-difenilpirazol 3-sustituidos utiles como moduladores de cb1.
ES2313304T3 (es) * 2004-02-24 2009-03-01 Glaxo Group Limited Derivados de piridina y su uso como moduladores del receptor cb2.
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
FR2867685B1 (fr) * 2004-03-17 2008-05-23 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement de la bronchite chronique et de la broncho-pneumopathie chronique obstructive
CN1938286A (zh) 2004-03-29 2007-03-28 默克公司 作为11－β－羟甾类脱氢酶－1抑制剂的二芳基三唑
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
RU2377238C2 (ru) * 2004-04-03 2009-12-27 Астразенека Аб Производные имидазола, активные в отношении рецептора св1
FR2869905B1 (fr) 2004-05-10 2008-09-05 Sanofi Synthelabo Procede de preparation d'ester de l'acide 1,5-diphenylpyrazole carboxylique.
EP1749002B1 (en) 2004-05-10 2009-05-27 F.Hoffmann-La Roche Ag Pyrrole or imidazole amides for treating obesity
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
TW200602314A (en) * 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
WO2007053131A2 (en) * 2004-06-04 2007-05-10 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as antibiotic agents
PE20060430A1 (es) 2004-06-09 2006-05-25 Glaxo Group Ltd Derivados de pirrolopiridina como moduladores de los receptores cannabinoides
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
EA011307B1 (ru) 2004-07-12 2009-02-27 Кадила Хелзкэр Лимитед Трициклические производные пиразола в качестве модуляторов каннабиноидного рецептора
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
US7915252B2 (en) 2004-08-06 2011-03-29 Merck Sharp & Dohme Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
CN101072769A (zh) * 2004-08-06 2007-11-14 第一制药株式会社 抗血小板药及其制造方法
JPWO2006014005A1 (ja) * 2004-08-06 2008-05-01 第一製薬株式会社 ピラゾール誘導体
GB0417910D0 (en) * 2004-08-11 2004-09-15 Novartis Ag Organic compounds
CA2577060A1 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
RU2394027C2 (ru) 2004-10-27 2010-07-10 Ф. Хоффманн-Ля Рош Аг Новые индольные или бензимидазольные производные
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ATE427759T1 (de) 2004-11-01 2009-04-15 Amylin Pharmaceuticals Inc Behandlung von fettsucht und verbundenen erkrankungen
WO2006050842A1 (en) 2004-11-09 2006-05-18 F. Hoffmann-La Roche Ag Dibenzosuberone derivatives
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
FR2880023B1 (fr) * 2004-12-23 2007-02-23 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
AR054417A1 (es) * 2004-12-23 2007-06-27 Astrazeneca Ab Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas.
EP1831177A1 (en) * 2004-12-23 2007-09-12 AstraZeneca AB Therapeutic agents
EP1844017A1 (en) * 2005-01-06 2007-10-17 Cadila Healthcare Ltd. An amorphous and three crystalline forms of rimonabant hydrochloride
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
WO2006074445A2 (en) * 2005-01-10 2006-07-13 Alexandros Makriyannis Novel heteropyrrole analogs acting on cannabiniod receptors
FR2880890B1 (fr) * 2005-01-19 2007-03-30 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide, leur preparation et leur application en therapeutique
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
FR2881744B1 (fr) 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
FR2882054B1 (fr) * 2005-02-17 2007-04-13 Sanofi Aventis Sa Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
FR2882263B1 (fr) * 2005-02-23 2007-04-06 Sanofi Aventis Sa Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique
RU2404164C2 (ru) 2005-04-06 2010-11-20 Ф.Хоффманн-Ля Рош Аг Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
CA2612079A1 (en) * 2005-06-22 2006-12-28 F. Hoffmann-La Roche Ag (6-flu0r0-benz0[1,3] dioxolyl)-morpholin-4-yl-methanones and their use as cb1 ligands
FR2887550A1 (fr) * 2005-06-24 2006-12-29 Sanofi Aventis Sa Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
FR2887548B1 (fr) * 2005-06-27 2007-09-21 Sanofi Aventis Sa Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
EP2308840A1 (en) 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
AU2006268680B2 (en) * 2005-07-11 2012-11-22 Msd Oss B.V. Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
EP1743636A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Combination of a substituted pyrazoline compound and a drug used in food-related disorders
WO2007131538A1 (en) * 2005-07-15 2007-11-22 Laboratorios Del Dr. Esteve, S.A. Azepane- or azocane-substituted pyrazoline compounds, their preparation and use as medicaments
ES2316306B1 (es) * 2005-07-15 2009-11-23 Laboratorios Del Dr. Esteve, S.A. Combinacion de un compuesto de pirazolina sustituido y un farmaco utilizado en trastornos relacionados con los alimentos.
EP1757588A1 (en) * 2005-07-29 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Polymorph of N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide and its use as a cannabinoid receptor modulator
EP1743637A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
EP1910300A2 (en) * 2005-07-15 2008-04-16 Laboratorios del Dr. Esteve S.A. Prodrugs of pyrazoline compounds, their preparation and use as medicaments
GB0514738D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
GB0514739D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
EP1752149A1 (en) 2005-07-29 2007-02-14 Laboratorios Del Dr. Esteve, S.A. CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression
WO2007017126A2 (en) * 2005-07-29 2007-02-15 Laboratorios Del Dr. Esteve, S.A. POLYMORPH OF N-PIPERIDINYL-5- (4-CHLOROPHENYL) -1- (2, 4-DICHLOROPHENYL) -4, 5-DIHYDRO-lH-PYRAZOLE- 3 -CARBOXAMIDE AND ITS USE AS A CAMNABINOID RECEPTOR MODULATOR
WO2007015162A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
CA2518579A1 (en) * 2005-08-05 2007-02-05 University Technologies International Inc. Method for appetite suppression
US20080221097A1 (en) * 2005-08-09 2008-09-11 Glaxo Group Limited Imidazopyridine Derivatives as Cannabinoid Receptor Ligands
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US20080193534A1 (en) * 2005-08-12 2008-08-14 Astrazeneca Ab Process
EP1757290A1 (en) * 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
GB0518819D0 (en) * 2005-09-15 2005-10-26 Astrazeneca Ab Therapeutic agents
BRPI0616263A2 (pt) * 2005-09-23 2011-06-14 Janssen Pharmaceutica Nv moduladores canabinàides do tipo tetrahidro-ciclopentil pirazol
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
EP1935881B1 (en) * 2005-09-30 2012-04-04 Msd K.K. Aryl-substituted nitrogen-containing heterocyclic compound
AR056560A1 (es) * 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
FR2894578B1 (fr) 2005-12-12 2008-02-01 Sanofi Aventis Sa Derives heterocycliques, leur preparation et leur application en therapeutique.
FR2894579B1 (fr) * 2005-12-12 2008-01-18 Sanofi Aventis Sa Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
CN100999517B (zh) * 2006-01-11 2010-12-15 北京摩力克科技有限公司 吡唑甲酰胺衍生物,药物组合物和其制备方法
CA2637565A1 (en) 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
MEP6808A (xx) * 2006-02-23 2010-02-10 Lundbeck & Co As H Priperidinoilpirodolini agonisti receptora menalokortina tipa 4
WO2007106721A2 (en) * 2006-03-10 2007-09-20 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
WO2007121466A2 (en) * 2006-04-18 2007-10-25 Dr. Reddy's Laboratories Ltd. Process for preparing rimonabant
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
US7803799B2 (en) * 2006-07-07 2010-09-28 National Health Research Institutes Selenophene compounds
EP1878723B1 (fr) * 2006-07-11 2010-05-26 Sanofi-Aventis Dérivés de N-[(1,5-diphényl-1H-pyrazol-3-yl)méthyl]sulfonamide antagonistes des récepteurs CB1 des cannabinoïdes
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
CA2658506C (en) 2006-07-20 2016-01-26 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab 1 inhibitors
EP2057144A4 (en) * 2006-09-01 2010-06-02 Hetero Drugs Ltd NEW POLYMORPHIC FROM RIMONABANT
NZ574710A (en) 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
US20100076197A1 (en) * 2006-09-11 2010-03-25 Hetero Drugs Limited Process for rimonabant
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
WO2008035023A1 (en) * 2006-09-19 2008-03-27 Cipla Limited Polymorphs of rimonabant
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
TWI339205B (en) * 2006-10-02 2011-03-21 Nat Health Research Institutes Pyrazole compounds and pharmaceutical composition
TWI408136B (zh) * 2006-10-02 2013-09-11 Nat Health Research Institutes 噻吩化合物及其醫藥組成物
WO2008063847A2 (en) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Method for treating autism
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
FR2909090B1 (fr) 2006-11-23 2009-01-09 Sanofi Aventis Sa Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
WO2008062480A2 (en) * 2006-11-24 2008-05-29 Ind-Swift Laboratories Limited An improved process for the preparation of rimonabant
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US8148404B2 (en) * 2006-12-18 2012-04-03 7Tm Pharma A/S Modulators of CB1 receptors
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
EA016507B1 (ru) 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
EA015129B1 (ru) 2007-01-04 2011-06-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
FR2911136B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
US20080182877A1 (en) * 2007-01-05 2008-07-31 Westheim Raymond J H Rimonabant forms and methods of making the same
WO2008088900A2 (en) * 2007-01-18 2008-07-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rimonabant base and processes for preparation thereof
TW200848039A (en) * 2007-02-09 2008-12-16 Astrazeneca Ab Pharmaceutical compositions
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
US8431609B2 (en) * 2007-02-19 2013-04-30 Darmesh Mahendrabhai Shah Process for preparation of pyrazole derivatives
WO2008101860A1 (en) * 2007-02-20 2008-08-28 Sandoz Ag Novel process for the preparation of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)pyrazole-3-carboxamide
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US7705024B2 (en) * 2007-04-12 2010-04-27 National Health Research Institutes Oxadiazole compounds
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
CN101314591B (zh) * 2007-05-30 2010-09-29 上海阳帆医药科技有限公司 吡唑类高选择性大麻受体-1拮抗剂和/或反向激动剂
CA2690004C (en) 2007-06-04 2018-01-23 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA200901656A1 (ru) * 2007-06-15 2010-06-30 Айрм Ллк СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ ITPKb
EP2548874A3 (en) * 2007-06-28 2013-05-15 Intervet International B.V. Substituted piperazines as CB1 antagonists
JP2010531874A (ja) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン
US8338623B2 (en) * 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
FR2919184A1 (fr) * 2007-07-26 2009-01-30 Sanofi Aventis Sa L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
WO2009063495A2 (en) * 2007-09-20 2009-05-22 Cadila Healthcare Limited Substituted indole and its derivatives as cannabinoid modulators
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
US20100323955A1 (en) * 2007-11-14 2010-12-23 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8829043B2 (en) 2008-02-08 2014-09-09 Nektar Therapeutics Oligome-cannabinoid conjugates
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
EP2103602A1 (en) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Novel 1,2,4-triazole derivatives and process of manufacturing thereof
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2151234A1 (en) * 2008-07-28 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
ES2421920T3 (es) * 2008-08-06 2013-09-06 Pfizer Ltd Compuestos de diazepina y diazocano como agonistas de MC4
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2350010B1 (en) 2008-10-30 2014-03-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
TWI434686B (zh) * 2008-11-03 2014-04-21 Nat Health Research Institutes 咪唑－４－酮及咪唑－４－硫酮化合物
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
KR101070176B1 (ko) * 2009-01-13 2011-10-05 (주)에스에이치제약 Ｃｂ１에 길항 활성을 갖는 1ｈ-파이라졸-3-아마이드계 화합물 또는 1ｈ-파이라졸-3-옥소아세트아마이드계 화학물 유도체 및 이를 포함하는 약제학적 조성물
WO2010093243A1 (en) 2009-02-12 2010-08-19 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
WO2011044370A1 (en) 2009-10-07 2011-04-14 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
JP5696156B2 (ja) 2009-11-02 2015-04-08 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
WO2011058193A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
WO2011079778A1 (en) 2009-12-30 2011-07-07 China Shanghai Fochon Pharmaceutical Co Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2569310A1 (en) 2010-05-11 2013-03-20 Pfizer Inc Morpholine compounds as mineralocorticoid receptor antagonists
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
CN102206182B (zh) * 2011-04-11 2013-03-13 中国药科大学 盐酸利莫那班的合成方法
CN102250006B (zh) * 2011-05-12 2014-03-05 范如霖 3-吡唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
WO2012174362A1 (en) 2011-06-17 2012-12-20 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
US9226505B2 (en) 2011-09-23 2016-01-05 Bayer Intellectual Property Gmbh 4-substituted 1-phenylpyrazole-3-carboxylic acid derivatives as agents against abiotic plant stress
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
DE102011055815A1 (de) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
JP2015504442A (ja) 2011-11-30 2015-02-12 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 殺菌性ｎ−ビシクロアルキルおよびｎ−トリシクロアルキル（チオ）カルボキサミド誘導体
KR101720885B1 (ko) 2012-06-19 2017-03-28 데비오팜 인터네셔날 에스 에이 (e)-n-메틸-n-((3-메틸벤조푸란-2-일)메틸)-3-(7-옥소-5,6,7,8-테트라히드로-1,8-나프티리딘-3-일)아크릴아미드의전구약물 유도체
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
AU2013326600B2 (en) 2012-10-02 2017-03-30 Bayer Cropscience Ag Heterocyclic compounds as pesticides
JPWO2014069554A1 (ja) * 2012-10-31 2016-09-08 東レ株式会社 キヌクリジンアミド誘導体及びその医薬用途
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014174457A1 (en) 2013-04-23 2014-10-30 Council Of Scientific & Industrial Research Pyrazole carboxylic acid analogues as anti-mycobacterial drug candidates
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR20160094956A (ko) 2013-11-05 2016-08-10 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 당뇨병 및 당뇨병으로부터 발생하는 합병증 질환의 치료를 위한 화합물
BR112016028119A2 (pt) 2014-06-06 2017-08-22 Res Triangle Inst Agonistas receptores de apelina (apj) e usos dos mesmos
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
CN106279029A (zh) * 2015-05-21 2017-01-04 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
MX2017016530A (es) 2015-06-22 2018-03-12 Arena Pharm Inc Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).
CN105061315B (zh) * 2015-08-06 2017-10-24 大连理工大学 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用
EP3386976A1 (en) * 2015-12-09 2018-10-17 Research Triangle Institute, International Improved apelin receptor (apj) agonists and uses thereof
LT3419628T (lt) 2016-02-26 2021-01-25 Debiopharm International Sa Medikamentas diabetinėms pėdų infekcijoms gydyti
MX2019004214A (es) 2016-10-12 2019-06-10 Res Triangle Inst Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos.
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US11111698B2 (en) 2016-12-05 2021-09-07 Endura Products, Llc Multipoint lock
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
KR101877002B1 (ko) * 2017-03-06 2018-07-12 서울대학교 산학협력단 피라졸 유도체를 유효성분으로 함유하는 소양증의 예방 또는 치료용 약학적 조성물 및 이를 검출하기 위한 스크리닝 방법
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
WO2019194207A1 (ja) 2018-04-04 2019-10-10 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
JP2023509452A (ja) 2020-01-03 2023-03-08 バーグ エルエルシー がんを処置するためのｕｂｅ２ｋモジュレータとしての多環式アミド
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof
US12054480B2 (en) 2020-07-31 2024-08-06 Makscientific, Llc Compounds for treating cannabinoid toxicity and acute cannabinoid overdose
TW202227417A (zh) 2020-08-18 2022-07-16 美商默沙東藥廠 雙環庚烷吡咯啶之食慾素受體促效劑

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3449350A (en) * 1968-06-24 1969-06-10 Ciba Geigy Corp Certain pyrazole-3-carboxylic acid hydrazide derivatives
ES497143A0 (es) * 1979-11-16 1982-04-01 Morishita Pharma Procedimiento para la fabricacion de derivados del pirazol
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US5164381A (en) * 1986-05-29 1992-11-17 Ortho Pharmaceutical Corporation Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same
US5051518A (en) * 1987-05-29 1991-09-24 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
AU611437B2 (en) * 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
US4898880A (en) * 1989-03-22 1990-02-06 Sterling Drug Inc. N-(heterocycle)alkyl)-1H-pyrazole-1-alkanamides as antiarrhythmic agents, compositions and use
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5117054A (en) * 1991-09-26 1992-05-26 Ortho Pharmaceutical Corporation N-hydroxy, N-methyl propanamides
IL105939A0 (en) * 1992-06-11 1993-10-20 Rhone Poulenc Agriculture Herbicidal compounds and compositions
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
HUT64526A (en) 1994-01-28
FR2692575A1 (fr) 1993-12-24
HU9301851D0 (en) 1993-09-28
FI932891A (fi) 1993-12-24
NO932296D0 (no) 1993-06-22
DE69308395T2 (de) 1997-10-16
IL120517A0 (en) 1997-07-13
FI932891A0 (fi) 1993-06-22
BR9302435A (pt) 1994-01-11
ES2101258T3 (es) 1997-07-01
US5624941A (en) 1997-04-29
DE69308395D1 (de) 1997-04-10
CZ289487B6 (cs) 2002-02-13
DK0576357T3 (da) 1997-09-15
AU664281B2 (en) 1995-11-09
NO302819B1 (no) 1998-04-27
HU218797B (hu) 2000-12-28
ATE149489T1 (de) 1997-03-15
AU4143893A (en) 1994-01-06
NO932296L (no) 1993-12-27
GR3023535T3 (en) 1997-08-29
HU222577B1 (hu) 2003-08-28
IL106099A0 (en) 1993-10-20
JP3238801B2 (ja) 2001-12-17
TW494096B (en) 2002-07-11
KR940000433A (ko) 1994-01-03
MY113022A (en) 2001-11-30
CA2098944C (en) 1999-09-07
BR1100409A (pt) 1999-10-13
MX9303664A (es) 1994-01-31
SK283399B6 (sk) 2003-07-01
FI113169B (fi) 2004-03-15
JPH0673014A (ja) 1994-03-15
SK65493A3 (en) 1994-02-02
FR2692575B1 (fr) 1995-06-30
NZ247961A (en) 1995-08-28
EP0576357B1 (fr) 1997-03-05
ZA934511B (en) 1994-02-22
EP0576357A1 (fr) 1993-12-29
CA2098944A1 (en) 1993-12-24
RU2119917C1 (ru) 1998-10-10
CZ117293A3 (en) 1994-03-16
KR100307050B1 (ko) 2001-11-30
IL106099A (en) 1998-07-15

Similar Documents

Publication Publication Date Title
UA27728C2 (uk) Похідні піразолу, що мають спорідненість до рецепторів канабіноїдів, спосіб їх одержання, фармацевтична композиція та проміжна сполука
RU93049108A (ru) Производные пиразола, способ их получения, содержащие их фармацевтические композиции и промежуточные соединения синтеза
AU5488498A (en) Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them
MY117274A (en) Polycyclic amine compounds and their enantiomers,their method of preparation and pharmaceutical compositions in which they are present.
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
HUP9900645A3 (en) Novel substituted imidazole compounds, pharmaceutical compositions containing them and process for their producing
RU94027577A (ru) Производные 1-бензолсульфонил-1,3-дигидро-2н-бензимидазол-2-она, способ их получения, содержащая их фармацевтическая композиция
IL72120A0 (en) 2-pyrimidinyl-1-piperazine derivatives,their preparation and pharmaceutical compositions containing them
HUP9600211A3 (en) Heterocyclic compounds, process for producing them and pharmaceutical compositions containing them, as an activ ingredient
IL112622A (en) Iminoalkylamino or aminoalkylideneamino camptothecin derivatives, process for their preparation and pharmaceutical compositions containing them
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
HUP9601033A2 (en) Benzofurane derivatives, process for their preparation, use of them as intermediate and pharmaceutical compositions containing the compounds
HUT77360A (hu) Apoliprotein-B szintézis inhibitor hatású azolszármazékok, eljárás előállításukra, a vegyületeket tartalmazó gyógyszerkészítmények és intermedierjeik
IL118366A0 (en) Vitamin D derivatives a process for the preparation thereof and pharmaceutical compositions containing the same
AU2001235596A1 (en) Novel 1,3-dihydro-2h-indol-2-one derivatives, preparation method and pharmaceutical compositions containing them
IE842930L (en) Furopyridines
WO1992014696A3 (en) SUBSTITUTED α-AMINOALDEHYDES AND DERIVATIVES
ZA952771B (en) Novel compound
MY120683A (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
BG102229A (en) Endothelium receptor antagonists
UA72883C2 (uk) Біциклічна сполука, способи її одержання, фармацевтичні композиції, що її містять,способи лікування та попередження різних захворювань, проміжні сполуки та способи їх одержання
EG20562A (en) Process for preparing glutaramide derivatives
CA2019409A1 (en) Organosilicon compounds and method for their preparation
HUT70556A (en) Quinoline derivatives, pharmaceutical compositions containing them and process for producing the compounds
HUT54355A (en) Process for producing imidazole derivatives of substituted benzoylurea, as well as antitumoural compositions comprising such compounds